论文部分内容阅读
目的：探讨Ｂｃｌ－２、Ｐ１７０ 在复发难治急性白血病表达的临床意义。方法：用ＡＢＣ免疫细胞化学方法检测７７ 例急性白血病Ｂｃｌ－２、Ｐ１７０ 的表达。结果：复发难治的急性白血病Ｂｃｌ－２、Ｐ１７０ 的表达显著高于初治者。Ｂｃｌ－２、Ｐ１７０ 高表达的急性白血病完全缓解率低，早期复发率高，预后差。Ｂｃｌ－２ 或Ｐ１７０ 高表达者，５０％ 为难治性白血病，二者同时高表达者均为难治性白血病。Ｂｃｌ－２ 与急性白血病预后的阳性符合率９０．９％ ，较Ｐ１７０ 略高。Ｂｃｌ－２ 与Ｐ１７０ 的表达呈轻度正相关（ ｒ ＝ ０．３８６， Ｐ ＜０．００１）。结论：Ｂｃｌ－２、Ｐ１７０ 的高表达是反映急性白血病复发、难治的重要指标。Ｂｃｌ－２ 的预测敏感性较高。不同的ＭＤＲ机制之间可能存在联系。
Objective: To explore the clinical significance of the expression of Bcl-2 and P170 in relapsed and refractory acute leukemia. Methods: The expression of Bcl-2 and P170 in 77 cases of acute leukemia was detected by ABC immunocytochemistry. Results: The expression of Bcl-2 and P170 in the relapsed and refractory acute leukemia was significantly higher than that in the newly treated patients. The complete remission rate of acute leukemia with high expression of Bcl-2, P170 is low, the early recurrence rate is high, and the prognosis is poor. In patients with high expression of Bcl-2 or P170, 50% were refractory to leukemia, and both were highly refractory to leukemia. The positive coincidence rate of Bcl-2 with acute leukemia was 90.9%, which was slightly higher than that of P170. There was a slight positive correlation between the expression of Bcl-2 and P170 (r = 0.386, P < 0.001). Conclusion: The high expression of Bcl-2 and P170 is an important indicator reflecting the relapse and refractory of acute leukemia. The prediction sensitivity of Bcl-2 is higher. There may be links between different MDR mechanisms.